The bone marrow microenvironment – Home of the leukemic blasts by Shafat, Manar S et al.
Accepted Manuscript
The bone marrow microenvironment – Home of the leukemic
blasts
Manar S Shafat, Bruno Gnaneswaran, Kristian M Bowles, Stuart
A Rushworth
PII: S0268-960X(16)30073-X
DOI: doi: 10.1016/j.blre.2017.03.004
Reference: YBLRE 478
To appear in:
Please cite this article as: Manar S Shafat, Bruno Gnaneswaran, Kristian M Bowles, Stuart
A Rushworth , The bone marrow microenvironment – Home of the leukemic blasts. The
address for the corresponding author was captured as affiliation for all authors. Please
check if appropriate. Yblre(2017), doi: 10.1016/j.blre.2017.03.004
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
The bone marrow microenvironment – home of the leukemic blasts 
 
Manar S Shafata, Bruno Gnaneswaranb, Kristian M Bowlesa,c, Stuart A Rushwortha* 
 
aDepartment of Molecular Haematology, Norwich Medical School, The University of 
East Anglia, Norwich Research Park, NR4 7UQ, United Kingdom 
b Norwich Medical School, The University of East Anglia, Norwich Research Park, 
NR4 7TJ, United Kingdom  
cDepartment of Haematology, Norfolk and Norwich University Hospitals NHS Trust, 
Colney Lane, Norwich, NR4 7UQ United Kingdom 
 
*Corresponding Author: 
Dr Stuart Rushworth 
Department of Molecular Haematology,   
Norwich Medical School, 
University of East Anglia,  
Norwich Research Park, 
Norwich, NR4 7TJ 
United Kingdom 
Tel.: +44 1603 591802 
E-mail: s.rushworth@uea.ac.uk 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Abstract 
Acute Myeloid Leukaemia (AML) is a genetically, biologically and clinically 
heterogeneous set of diseases, which are characterised by an increased growth of 
abnormal myeloid progenitor cells within the bone marrow (BM). Ex-vivo AML 
exhibits a high level of spontaneous apoptosis. Furthermore, relapse for patients 
achieving remission occurs from minimal residual disease harboured within the BM 
microenvironment. Taken together, these observations illustrate the importance of 
the BM microenvironment in sustaining AML. While significant progress has been 
made elaborating the small-scale genetic mutations and larger-scale chromosomal 
translocations that contribute to the development of AML and its prognosis in 
response to treatment, less is understood about the complex microenvironment of 
the BM, which is known to be a key player in the pathogenesis of the disease. As we 
look towards future therapies, the consideration that the BM microenvironment is 
uniquely important as a niche for AML - coupled with the idea that leukaemic blasts 
are more likely to be genetically unstable and therefore evolve resistance to 
conventional chemotherapies - make the functions of the non-malignant cells of the 
BM attractive targets for therapy. In this review, we discuss the microanatomy of the 
BM and provide an overview of the evidence supporting the role of the BM 
microenvironment in creating conditions conducive to the survival and proliferation of 
AML blasts. Ultimately, we examine the therapeutic potential of uncoupling AML from 
the BM microenvironment. 
 
Keywords: bone marrow, acute myeloid leukaemia, bone marrow 
microenvironment. 
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1. Introduction 
 
The survival of patients with Acute Myeloid Leukaemia (AML) is presently poor. Two-
thirds of younger adults and 90% of older adults die of their disease1. Even in 
patients who achieve remission with chemotherapy, relapse is common and occurs 
from minimal residual disease sequestered in protective niches in the bone marrow 
(BM) microenvironment.  
The malignant blasts that form the AML tumour are presently understood to 
represent a variety of clinically, morphologically, genetically and epigenetically 
heterogeneous tumours collectively grouped under the classification of AML2-5. Even 
within individual patients, AML is now recognised as a number of distinct sub-clones 
of the disease, 3 and that these sub-clones evolve within patients as the disease is 
treated leading to potential relapse and progression.  
Despite this inter- and intra-tumour heterogeneity, AML clones share many 
fundamental features. Clinically, these tumours are mitotically highly active, 
progressing rapidly within the patient. Historically, they have been clinically treated in 
a similar way (with the exception of acute pro-myelocytic leukaemia). Presently, 
treatment for those fit enough to withstand intensive therapy consists of multi-agent 
cytotoxic chemotherapy regimens with or without allogeneic stem cell transplant. 
Patients who are unfit for such intensive treatment may be managed with hypo-
methylating agents and/or with supportive/palliative care.  Biologically, all AMLs arise 
from myeloid haematopoietic progenitors and are characterised by the rapid 
accumulation of abnormal haematopoietic progenitor cells (HPC) within the BM. In 
addition to tumours, leukaemic stem cells (LSCs) or leukaemia-initiating cells (LICs), 
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a subpopulation of AML cells that have long-term repopulating potential, reside in the 
BM microenvironment and harbour one or more of the oncogenic mutations driving 
tumourigenesis. Relapse from AML is common and in such patients the cause of 
leukemic relapse is primarily due to remnant LSCs in the BM following 
chemotherapy. Leukaemia like most haematological malignancies, can mobilise from 
bone marrow to blood and the lymphatic system. It’s also interesting to note that 
LICs can also be found in other sites including skin, the central nervous system 
(CNS) and other organs. 6, 7.   
Accordingly, as all AML are dependent on the BM microenvironment, it has been 
hypothesised that better patient outcomes may come from novel treatment strategies 
derived from improved understanding of the biology of AML within the BM 
microenvironment8. Importantly, these treatments could be widely applicable to 
patients with AML across a spectrum of genetic subtypes. 
Acute lymphoblastic leukemia (ALL), (another haematological malignancy of a 
heterogeneous nature, characterised by B-cell and T-cell progenitors) has also been 
studied in detail for its dependence on the BM microenvironement. While the survival 
outcomes of paediatric cases of this disease have greatly improved in the last six 
years, adult cases still carry a severe prognosis 9, 10. Much like AML, relapses are 
attributed to the minimal residual disease of a pool of LIC in dormancy which are 
unaffected by chemotherapies, which target cycling cells. Various interactions 
between ALL cells and the microenvironment have been implicated in the 
progression of this disease; one of the most widely studied interactions is that of the 
BM fibroblasts and the ALL wherein the BM fibroblasts provide better support and 
survival for the B-cell ALL lineage11.  
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In this review, we will highlight the fundamental importance of the BM in normal 
human haematopoiesis and will further investigate the key role(s) of the cell types 
therein in providing an environment that contributes to the survival, growth and 
migration of AML cells. The potential for inhibitory measures against the activity of 
these non-cancerous BM cells as a means for targeting AML survival will also be 
explored.  
 
2. The bone marrow microenvironment and haematopoiesis 
 
The BM is a soft viscous tissue that occupies cavities within the bone12. It is 
comprised of blood vessels and a heterogeneous population of cells that are either 
directly involved in the BM’s primary function of haematopoiesis, or act in support of 
haematopoietic cell function via the cell types surrounding the haematopoietic cells. 
These supporting cells in the BM all contribute to the stimuli required for regulating 
normal haematopoiesis (Table 1). The bone marrow stromal cells, also called 
mesenchymal stem cells (MSC), are responsible for the establishment of the 
haematopoietic microenvironment as they reside in the bone marrow and give rise to 
cells such as marrow adipose tissue, bone cartilage and occasionally myofibres that 
are defined by their ability to differentiate into such cells13. A commonly shared view 
on MSCs is that they are ubiquitous in connective tissue and are phenotypically 
similar to skeletal progenitor cells and pericytes. In recent years, efforts have been 
made in this field to clearly define what MSCs are and how they can be better 
defined. A pioneer in the field of bone and marrow cell biology and development, 
Bianco et al., has recently identified a progenitor for these BM MSCs and has 
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redefined them more stringently, based on  in vivo differentiation capability, as 
skeletal stem cells (SSC) 14, 15. These cells are found on the surface of the blood 
vessels of the bone marrow (sinusoids) (Figure 1). Bianco et al. went further to prove 
that MSCs are not ubiquitous, have a different transcriptome for MSCs of different 
anatomical regions and are identified as CD34-/CD45-/CD146+ cells17.  
Due to the compartmental and heterogeneous nature of its stromal system, the BM 
is recognised as an organ with two separate yet co-operative systems exhibiting 
functional co-dependence: the haematopoietic tissue system and its associated 
supporting stromal tissue system. Originally, much interest was focused on the 
supporting nature of the stromal system and its contribution to haematopoiesis; 
however, recent studies have brought to light the unanticipated differentiation 
potential of stromal cells into special cell types that are phenotypically distinct from 
cells from the tissue of origin, an attribute termed ‘transgermal plasticity’ 17 The 
identification of this characteristic poses an exciting potential in terms of its 
manipulation for therapeutic applications. Plasticity of BM stromal cells could hold 
the key in identifying the switch from normal to malignancy-associated stromal cells 
and thereby identify a new field of therapeutic strategies for BM malignancies. 
Haematopoietic stem cells (HSCs) reside in the BM and remain there until 
maturation. Here, they differentiate along one of two core lineages: the common 
lymphoid progenitor (CLP) line or the common myeloid progenitor (CMP) line. CLPs 
and CMPs  subsequently differentiate into either leukocytes of the adaptive immune 
system (T cells and B cells), or cells of the megakaryocyte/erythrocyte lineage and 
granulocyte/macrophage lineage, respectively.  
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Table 1. Types of BM cells 
Stromal cell type Location Function 
Adipocytes Central core that constitutes 
the yellow marrow 
Indirectly but negatively 
regulate normal 
haematopoiesis 18 
Endothelial cells Sinusoidal: Lining the 
sinusoids that infiltrate the 
red marrow 
Arteriolar: Lining of the 
arterioles originating from 
arterial vessels entering the 
marrow cavity through 
foramina nutricia  19 
Enable the exchange of 
molecules between the blood 
and surrounding bone 
marrow 20 
Fibroblasts Red marrow Synthesise structural 
components of marrow such 
as collagen 21 
Osteoblasts Cortical regions of the red 
marrow 
Synthesise bone tissue and 
regulation of BM 
angiogenesis 22 
Osteoclasts Cortical regions of the red 
marrow 
Resorb bone tissue 22, 23 
Chondrocytes Cambium layer of the 
periosteum 
Cartilaginous tissue synthesis 
24 
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Collectively, recent investigations have suggested that the BM can be divided into 
compartments termed ‘niches’ wherein the non-haematopoietic cells interact to 
influence several HSC functions, including proliferation, differentiation, adhesion and 
quiescence by producing a variety of cytokines, chemokines and other soluble 
factors 25, some of which are included in Table 2. The concept of a HPC and HSC 
niche, the constituents of which regulate cell fate, was first proposed by Schofield in 
1978 with further studies highlighting the role of haematopoietic progenitor and stem 
cell (HPSC) niches in physically anchoring stem cells to the extracellular matrix 
(ECM) 26. Recent studies have ascertained the specific regulators of HSCs and their 
progenitors in the BM, and have uncovered how a perturbation to one cell type can 
lead to an effect in another cell type without direct physical interaction between the 
two 27, 28. The heterogeneous nature of HSCs has given rise to speculation that there 
could be specialised niches for particular types of HSCs and their progeny within 
each class of niche 29.  
Table 2. AML microenvironment signalling axis 
Receptor Ligand Function References 
CXCR2 IL-8 Chemotaxis 30 
CXCR4 SDF-1 Chemotaxis 31 
IL6R IL-6 Immune response, haematopoiesis, 
acute phase response and 
inflammation 
32 
LFA ICAM-1 Leukocyte adhesion 33 
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VLA-4 VCAM-1 Adhesion, signal transduction 34 
RANK RANKL Bone remodelling 35 
FAT/CD36 FFA Transporter/regulator of fatty acid 
transport 
36 
 
3.  Haematopoiesis in the BM niche 
 
Many cells and their signals regulate haematopoiesis. Supporting cells within 
individual niches produce ligands and molecules that interact with their counterparts 
on the surface of HSCs, which contribute to several cellular functions.  Recent 
studies have pointed towards migration as being of considerable importance across 
the different niches within the BM.  Secretion of CXCL12 (a stromal-cell derived 
factor) along with other factors including IL-6, IL-8 and MCP-1 by MSCs has been 
shown to control HSPC retention in the BM37.  SDF-1 is of particular importance to 
the retention of HSPCs in the BM through binding and activation of the CXCR4 
receptor on HSPCs38. CXCR4 belongs to the C-X-C chemokine receptor family and 
is a G-protein-coupled receptor that is predominantly found on the surface of 
leukocytes. The primary function of CXCR4 is the regulation of leukocyte trafficking 
in haematopoiesis as well as during innate or acquired immune responses. By 
engaging CXCR4, CXCL12 is able to induce a rise in intracellular calcium ion levels, 
which consequently drives a chemotactic response39. The CXCL12/CXCR4 
signalling axis has been widely studied in the context of leukaemia. One important 
study in this field showed that immunocompromised mice models had an increased 
blast circulation following CXCR4 antagonist introduction which consequently 
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enhanced the effect of chemotherapy-induced apoptosis. These effects are now 
being tested in clinical trials 40 . Other studies have implicated CXCL12 and CXCR4 
binding in CD34+ cells as a trigger for the production of VLA-4 and lymphocyte 
function-associated antigen-1 (LFA-1). These in turn induce CD34+ cell adhesion to 
structures that carry vascular cell adhesion molecule-1 (VCAM-1) and intracellular 
adhesion molecule-1 (ICAM-1).  Taken together, these studies illustrate the 
importance of SDF1/CXCR4 interactions in adhesion and retention of cells in the BM 
as a means of regulating normal haematopoiesis 
4. The leukaemia–favourable microenvironment 
 
The promotion of AML survival and proliferation by the BM microenvironment comes 
at the expense of the development and production of normal haematopoietic cells. 
Consequently in AML, there is a physiologic failure of the BM to produce adequate 
numbers of mature blood cells and platelets? and the impedance of maturation of the 
HSCs within the leukaemic BM41. BMSCs (including endothelial cells and fibroblasts) 
have all been shown to be manipulated by the AML blast42-44. This ultimately allows 
AML to reshape the microenvironment in a way that supports AML blast survival and 
proliferation. A schematic of the BM cell components and their interactions with the 
leukemic blast is illustrated in Figure 2. 
 
4.1 Bone marrow stromal cells 
Changes in expression of the adhesion molecules, cell cycle regulators and pro-
angiogenic factors of BMSCs impart many features to malignant cells including pro-
growth, anti-apoptotic and pro-invasive phenotypes45. The changes brought about in 
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the stroma by the presence of leukaemic cells have been shown to reflect alterations 
in their cytokine and chemokine profiles. BMSC secretion of IL-6, a pro-inflammatory 
cytokine, has been shown to protect AML via JAK/STAT pathway activation and 
other pro-survival pathways via integrin-linked kinases46. IL-8, a chemokine involved 
in chemotaxis, has recently been shown to be an important potential target for AML 
therapeutic strategies47. Schinke and colleagues have shown that IL-8 and its 
receptor CXCR2 were consistently highly expressed in CD34+ cells from the pre-
AML disorder myelodysplastic syndrome (MDS). IL-17, a cytokine responsible for 
inducing and mediating pro-inflammatory responses, has also been implicated in 
BMSC change with IL-17 signalling-related genes being over-expressed30, 47. Indeed, 
the therapeutic relevance of BMSCs has been demonstrated by several studies that 
show that co-culture of cancer-associated BMSCs with cancer cells induces 
proliferation and confers drug resistance 48-50. This occurs either through intercellular 
contact or via the secretion of soluble factors51, 52. Evidence is accumulating that 
such alterations may also be relevant to AML, with one of the first studies to examine 
this demonstrating that direct cellular contact between AML blasts and adherent 
long-term stroma significantly decreased apoptosis of AML blasts53. This was 
followed by further studies showing that BMSCs provided protection against 
spontaneous and drug-induced apoptosis through direct contact with HS-5, a human 
stromal cell line54. Another recent study concluded that chemotherapeutic resistance 
could be conferred by activation of c-Myc in AML cells by the BMSCs48. Our own 
work has identified a novel pathway in which the chemokine macrophage inhibitory 
factor stimulates the BMSC to produce interleukin-8 which creates a pro-tumoral 
microenvironment.  
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The importance of BMSCs in initiating leukaemia was illustrated by experiments in 
which Phosphatase and tensin homolog (PTEN) deletion (tumour suppresser gene) 
in HSCs alone did not result in a proliferative phenotype; rather it depleted HSCs. By 
contrast, deletion of PTEN in both HSCs and cells of the BM resulted in malignant 
cell proliferation55. One study providing an insight into the interdependent 
relationship between the non-haematopoietic compartment and the 
myeloproliferative cells suggests that a pre-malignant state can be instigated by 
dysregulated non-haematopoietic cells. In this study, selective IκBα deletion in 
myeloid lineage of cells did not initiate a myeloproliferative disturbance, however a 
ubiquitous deletion of IκBα led to myeloproliferative disorder56. Together, these 
studies demonstrate the complex relationship between both haematopoietic and 
non-haematopoietic subpopulations of the BM. It is evident through several studies 
that the BMSCs play a critical role in the survival, proliferation and protection of 
leukaemic cells with the derivatives of BMSCs each playing an interdependent role in 
the sustainability and metastatic preference of these cells. 
 
 
4.2 Endothelial cells and fibroblasts  
4.2.1 Endothelial cells 
Anatomically, endothelial cells are located in the sinusoid of the bone in close 
proximity to other cells types within the BM environment. Their location suggests a 
role as gatekeepers that regulate the movement of cells between the BM and the 
circulation57. Studies have hypothesised that the vascular network of the BM 
provided by the endothelial cells may serve as a protective environment that could 
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be advantageous to AML cells58. Matrix metalloproteinases (MMPs) are a group of 
enzymes structurally related to endopeptidases and are involved in the destruction of 
the extracellular matrix (ECM) by reabsorbing its macromolecules. They contribute 
towards connective tissue remodeling but also its pathological destruction. In 
addition to their structural role in the vasculature, endothelial cells also express E-
selectin to which molecules on the surface of leukaemic cells are able to adhere. 
Another critical receptor of AML homing to and within the BM is very late antigen 4 
(VLA-4), which is an α4β1 integrin that facilitates adhesion of AMLs to cellular 
vascular cell adhesion molecule-1 (VCAM-1). This pathway has been proven to be 
involved in leukaemic blast adhesion to vessel walls and is a key player in migration 
and survival of these cells59. As well as facilitating the spread of malignant cells, 
adhesion also encourages endothelial cells to proliferate via the VEGF-activated 
Notch/DII4 pathway, thereby rewiring the system to promote rampant 
angiogenesis60. In addition to blast survival, retention and proliferation, adhesion of 
these blasts to tumour-associated endothelial cells protects cells from 
chemotherapy-induced cytotoxicity61.  
 
 
4.2.2 Fibroblasts 
The requirement of fibroblasts in AML progression was demonstrated upon co-
culture of AML blasts with normal BMSCs and two fibroblast lines (HLF1 and Hs27), 
which the latter were partitioned by a semi-permeable membrane. In the absence of 
fibroblasts, the AML cells exhibited reduced proliferation, a reduced ability to evade 
apoptosis and lower levels of IL-843. This suggests that contact between fibroblasts 
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and malignant blasts is important for the survival and migration of the cancer cells. 
EMMPRIN, also known as CD147, is a glycoprotein located on the surface of human 
tumour cells, and has been shown to stimulate tumour cells and stromal cells to 
produce higher levels of MMPs, resulting in ECM degradation and elevating tumour 
growth and metastasis62. Studies have shown that EMMPRIN can promote the 
release of MMP2 from fibroblasts in breast cancer 63 and several other tumour cell 
types64. However, little is known regarding MMP movement and how their activities 
are controlled once the target has been acquired65. Fu and co-workers demonstrated 
that the co-expression of EMMPRIN and VEGF in AML predicted poor clinical 
prognosis66. Moreover, it has recently been shown that EMMPRIN knockdown in the 
AML cell line U937, induced apoptosis; demonstrated anti-proliferative effects and 
also enhanced the activity of the cytotoxic drug Adriamycin67.  
 
The role of angiogenesis in many types of cancer - including AML - has been widely 
reported 42, 68, 69 and in theory represents a promising therapeutic target. Pro-
angiogenic factors, which encompass VEGF, FGF, IL-8 and the MMPs, are released 
from BMSCs and osteoclasts, often stimulated by contact between AML cells and 
BMSCs, or changes at the genetic or transcriptional level. Gene expression 
signatures that identify a core set of angiogenic genes that may serve to identify 
angiogenic activity have been developed with broad applicability across many 
tumour types. These signatures, achieved by an integrative meta-analysis of several 
cancer types, delineate the underlying transcriptional pathways of angiogenesis. 
Interestingly, EGF, latrophilin and seven transmembrane domain- containing 1 
(ELTD1), an unstudied G-protein coupled receptor and a highly ranked gene in the 
common angiogenesis signature, was shown to be significantly upregulated in 
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endothelial cells associated with solid tumours including renal, head and neck, 
colorectal, and ovarian cancer 70. This evidence points to the importance of 
angiogenesis in terms of tumour regulation and the importance of ELTD1’s role as a 
prognostic marker. Endothelial cells and fibroblasts control much of angiogenesis 
with fibroblasts synthesising the collagen and ECM that (i) provides the critical 
support required for vascularisation and (ii) releases the pro-angiogenic factors that 
recruit endothelial cells, which then line the blood vessels that penetrate the tumour 
mass. 
 
4.3 Osteoclasts and osteoblasts  
The homeostatic regulation of bone formation and reabsorption is often disrupted in 
malignancies of the BM. The result is progressive demineralisation of the bone 
driven by elevated osteoclast formation71. In multiple myeloma, the molecules 
implicated in this upregulation include RANKL, MIP1a, IL3 and IL672. RANKL is 
upregulated as a consequence of BMSCs binding cancer cells, which in turn 
instigates the binding of RANKL to its receptor on the surface of osteoclasts, hence 
preventing them from undergoing apoptosis73.  Evidence from allogeneic stem cell 
transplantation shows RANKL’s counterpart, RANK, to be expressed on NK cells, 
which play a key role in immunosurveillance in AML. Driven by this evidence, recent 
studies have investigated the involvement of the RANKL/RANK signalling axis in NK 
and AML cell interaction. A study by Schmiedel and colleagues proposed that a 
RANKL-mediated “vicious cycle” is able to circumvent NK cell surveillance of AMLs.  
35. This hypothesis was drawn from observation of a feedback loop involving an 
upregulation of RANK on NK cells. RANKL-induced inhibitory effects allows RANK 
interaction with AML-expressed RANKL, which subsequently activates a bidirectional 
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signalling cascade that enables RANK-facilitated inhibitory signals’ delivery to NK 
cells. This maintains a reversal of RANKL signalling in AML cells74. Therefore, 
targeting RANKL may enhance the anti-tumour action of NK cells in AML. 
Osteoblasts have been the subject of a direct study in AML wherein 
immunocompetent mouse models were demonstrated to have reduced levels of 
osteocalcin, a secretary factor that promotes bone formation75.  This phenomenon 
was observed in the absence of a substantial elevation in osteoclast numbers 
suggesting that unlike in myeloma, the osteoblastic arm in AML is of more 
importance than the osteoclastic aspect. 
 
4.4 Adipocytes 
Adipocytes are MSC derivatives and make up the majority of yellow marrow, which 
has been observed to expand with age. The abundance and proximity of fat cells to 
the leukaemic core coupled with work in other tumour types 76-78 has led to the 
hypothesis that such cells may well be involved in the deregulation of cellular 
energetics that is a hallmark of cancer. Physiologically, obesity is associated with 
poor clinical outcomes in leukemic patients 79 suggesting that in the context of 
cancer, adipose tissue may be a contributing factor to treatment resistance and 
relapse. In the context of haematology, Han et al. showed that adipose tissue can 
act as a reservoir for hematopoietic stem and progenitor cells 80 which supports the 
above notion that adipose tissue contributes to cancer protection and disease 
relapse. The proinflammatory element of leukaemia associated adipose tissue has 
been identified as a lipolysis-stimulating factor that contributes to adipose tissue 
atrophy in cancer81, 82. Lipolysis in adipocytes and fatty acid oxidation in AML cells 
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were the processes discovered to be underlying this phenomenon that has been 
described as a “metabolic symbiosis”77. One recent investigation into the role of 
adipocytes and free fatty acids in AML has uncovered that free fatty acids from BM 
adipocytes are able to activate a transcriptional programme that has been correlated 
with AML cell survival83. This investigation also reported fatty acid oxidation-
dependent metabolism of the AML cell line U937, when co-cultured with MSC-
derived adipocytes. An upregulation of pro-migratory and adhesion protein pathways 
along with a repression of oxidative phosphorylation was also reported in these co-
cultured AML cell lines. Pharmacological inhibition of fatty acid oxidation (by 
inhibiting carnitine palmitoyltransferase 1a (CPT1a), which is a fatty acid chaperone, 
into the mitochondria) was reported to decrease the pro-survival effects of 
adipocytes on AML. Moreover, Lee and colleagues identified avocatin B (inhibitor of 
fatty oxidation (FAO)) to be a potent inhibitor of AML survival and proliferation84. In 
the context of fatty acid transfer, a recent candidate for targeted fatty acid transfer 
inhibition is CD36. Ye et. al. have shown that LSCs can be categorised into two 
distinct CD36+ and CD36- subpopulations with the CD36+ subpopulation displaying 
an increased FAO activity and drug resistance profile81. 
Several studies have shown that adipocytes promote resistance of cancer cells to 
conventional chemotherapies85, 86. One study in particular has shown that adipocytes 
confer breast cancer cell resistance to antibody-dependent cellular cytotoxicity by 
trastuzumab87. These crucial findings suggest that there is crosstalk between the 
cancer-associated adipocytes and the cancer cells. This is because the 
transcriptional activation of genes that regulate lipolysis in the adipocytes and fatty 
acid oxidation in the cancer cells act in concert with several other pathways including 
migration, adhesion and vascularisation. This hypothesis is further supported by a 
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study in which leukaemic cell subpopulation resident in the bone marrow adipose 
tissue are protected from chemotherapy81. 
More recently, our own work and that of another group has shown that AML relies on 
adipcytes for there survival and proliferation within the BM 83, 88. Both groups show 
that the fatty acid chaperoning protein fatty acid binding protein 4 (FABP4) is 
increased in expression in the BM adipocyte when cultured with AML. Moreover, 
pharmacoligical targeting or knockdown of FABP4 reverses the protection of the 
conveyed by the adipocyte to the AML 83, 88.  We highlight through RNA-seq data of 
leukemic cells isolated from BM, peripheral blood and normal CD34+ cells that 
expression of FABP4 is also high in leukemic blast which is haboured in the BM. 
This suggests that directly targeting FABP4 or targting the pathway using inhbitors of 
B-oxidation is a potential therapy when combined with convential AML 
chemotherapy.  
 
 
4.5 CXCR12–abundant reticular cells  
CXCL12–abundant reticular cells (CAR) have been identified as high CXCL12 
expressing reticular cells in the bone marrow forming a network like structure located 
in the perivascular region of the bone marrow. These cells surround the sinusoidal 
endothelial cells or are located near the endosteum and have the potential to 
differentiate into osteoblasts or adipocytes, forming a specialised niche for the 
HSCs89, 90. As previously mentioned, CXCL12/CXCR4 interaction is of particular 
interest in leukaemia in terms of its role in adhesion and migration. CXCR4 is 
expressed in both myeloid and lymphoid lineages of leukaemic cells, with its ligand 
SDF-1 secreted by the stromal cells in the bone marrow. Tavor et. al. have shown 
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these cells to be of significance for the collective retention of leukaemic blasts within 
the bone marrow 91 and targeting CXCR4 has been shown to upset migration and 
retention in the bone marrow, thus making it more susceptible to cytotoxic therapies 
59, 92. Furthermore, these cells also express adipocyte-associated PPARγ and 
osteoblast differentiation-associated transcription factor RUNX2 and Osterix, the 
disruption of which significantly impacts the number of HSPCs and the B cell and 
erythroid progenitors. The abundant CXCL12 release from these cells and the role of 
their differentiating capacity along with the release of various lineage dependant 
cytokines make these cells viable candidates for targeting factors crucial for 
leukemic blast retention and migration.  
 
4.6 Sympathetic Neural cells 
It has long been known that the arterioles that compose the BM microvasculature are 
innervated by the sympathetic nervous system (SNS)93. Accordingly, for many years 
the function of the SNS within the BM context was believed to be associated with the 
BM cell mobility94. Over 30 years ago, a study in which the BM was denervated 
produced an increase in the number leukocytes circulating in the peripheral blood 95. 
Since then, there have been a number of studies conducted to investigate the role of 
adrenergic modulation of haematopoiesis. Despite these efferts, the role of 
sympathoadrenergic modulation of haematopoiesis is underexplored.  
Recent evidence has shown that mobilisation of HSCs is enhanced by chemical 
stimulation of the β2 adrenergic receptor
94. The same study also showed that 
adrenergic neurotransmission controls granulocyte-colony stimulating factor (G-
CSF)-induced mobilisation of HSCs, thus, further emphasising the role of the SNS in 
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migration of BM stem cells within their microenvironment. In the context of 
leukaemia, malignancy-containing BMs have been shown to have a reduced number 
of sympatho-adgrenergic fibres and supporting MSCs in mice that harbour human 
JAK2 mutations. This reduction in MSCs results in the release of cytokines that 
favour the proliferation of abnormal HSCs within the BM, thereby accelerating the 
course of the disease. Upon treatment with β3-adrenergic receptor stimulators, 
supporting MSCs are restored due to an apparent regulation by the restored 
sympathetic systems therein96. This report identified regulation of the neural capacity 
in the BM as a potential therapeutic target. Another recent study, that complements 
the above, investigated the role of the SNS in AML and described a novel 
mechanism by which leukaemic cells take advantage of the microenvironment and 
succumb to sympathetic neuropathy. The authors found that chemical removal of 
adrenergic nerves resulted in increased levels of leukaemic cell infiltration. This 
created a remodelled environment that favoured leukaemic cell expansion and 
malignancy-associated MSCs at the expense of healthy HSCs and their accessory 
cells97. Taken together, manipulation of the SNS can potentially preserve healthy 
HSCs and limit LSC development, and thus represents a promising therapeutic 
target. 
 
5. Therapeutic opportunities in targeting AML and the BM 
microenvironment 
 
Current and prospective systemic therapies for AML can be divided into at least 
three types: non-selective chemotherapies, immunotherapies and AML cell-targeted 
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therapies such as kinase inhibitors. Chemotherapies are typically administered with 
the aim of depleting the BM cell population. Stem cell or BM transplants may follow 
the depletion-based approach in selected patients. The primary drawback of 
chemotherapy is rooted in its non-selectivity, which results in a relatively high 
adverse effect profile that is often intolerable for older, frailer patients. Despite 
holding much promise, immunotherapies for AML are in the very early stages of 
development, are costly and may be very poorly tolerated in certain subpopulations 
of patients98. Notwithstanding some success, trials of AML cell-targeted therapies 
have been beset by the development of resistance in substantial numbers of AML 
patients. The genetic heterogeneity among the malignant cells of a substantial 
proportion of AML patients enables the rapid evolution of cellular mechanisms that 
confer resistance99. 
For this reason, two related albeit alternative approaches have been proposed: one 
that targets the LSCs that constitute the seed, and another that targets the BM 
microenvironment that is the soil to the LSC seed100. 
Table 3. Potential Inhibitors of signalling axis within the BM microenvironment 
Targets Potential 
inhibitors 
Mechanism References 
Angiogenesis Bevacizumab Monoclonal antibody 
that binds to VEGF and 
blocks receptor binding. 
101 
Combretastatin Tubulin binding agents 
that induce vascular-
102, 103 
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mediated necrosis 
CD147 inhibitor EMMPRIN silencing has 
shown to inhibit 
leukemia proliferation 
and increase 
chemosensitivity in vitro 
67 
Sunitinib Inhibits VEGFR1 and 
VEGFR2 signalling by 
inhibiting RTK 
104 
Trenananib Ang-1/2 neutralising 
peptide inhibiting its 
binding to Tie2 receptor 
105 
Migration Ibrutinib  
 
BTK inhibitor and 
inhibits AML migration 
and adhesion by 
targeting 
CXCR4/CXCL12 axis.  
92 
AMD3100 
 
CXCR4 antagonist and 
HSC mobilising agent. 
106, 107 
SB-332235 Competitive inhibitor of 
CXCR2 over CXCR1. 
Block IL-8/CXCR2 
binding and decreases 
30 
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AML viability. 
FAO 
Metabolism 
Sulfosuccinimidyl 
oleate 
Inhibits fatty acid uptake 
and sensitises leukemia 
to chemotherapy 
81 
3-KAT inhibitors Inhibits the catalysis of 
the last step of FAO 
108 
 
5.1 Targeting LSCs: the seed 
There is now clear evidence that the leukaemic microenvironment is essential for the 
growth and proliferation of AML. However, there is the identification of features of 
LSCs that are potentially druggable and consistent in their absence on normal 
HPSCs is one selective way of targeting malignant cells in AML. One of the first 
characterisations of LSCs was conducted by Bonnet and colleagues in AML109. They 
described a subpopulation of CD34+ CD38- human AML cells, which were able to 
constantly and progressively relocate themselves in a mouse xenograft model. 
Recently, Taussig and colleagues demonstrated that LSCs exhibit considerable 
phenotypic heterogeneity, hinting at a presence in different fractional populations 
with varying intensities of CD34 and CD38 expression, and not exclusively in a 
CD34+ CD38-   population110. This work highlighted the need to identify aberrant 
surface antigen expressions that specify LSC populations that can facilitate clinical 
monitoring strategies and the detection of minimal residual disease. These aberrant 
surface antigens can be used as markers for differentiating between healthy HPSC 
and LSCs. Therefore examining the LSC markers to identify novel targets are being 
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studies for potential immunotherapies. Recently, CD123 has shown promise in this 
regard as a marker specific to LSCs. CD123 is the IL-3RA receptor involved in 
proliferation, growth and differentiation of HPSCs. It was first reported as being 
expressed on the CD34+ CD38- cells of AML patients but not on the CD34+ CD38- 
cells of normal patients. Subsequent to this finding, Jordan and colleagues also 
showed that NF-ᴋB activity was higher in CD123+ CD34+ AML cells than in CD123+ 
CD34+ normal HPSCs111.  CD47 is another among the repertoire of promising LSC-
specific markers demonstrated to have been linked with worse prognosis. Under 
normal homeostasis, this molecule is only expressed on HPSCs when these cells 
migrate out of the endosteal niche. The therapeutic potential of this target was 
revealed by monoclonal antibody blockade of CD47, which led to an elevation of 
phagocytosis and a reduction in LSC engraftment. The resistance-conferring 
capacity of LSCs has also come under scrutiny as a potential target for AML therapy. 
In order to confirm the localisation of the resistance-conferring capacity of AML, 
Ishikawa, et al. used immunodeficient/interleukin (NOD/SCID/IL)2r gamma(null) mice 
to show that LSCs are able to engraft AML and retain their self-renewing capability in 
vivo where they move to osteoblastic area of the BM, become quiescent and are 
protected from chemotherapy-induced apoptosis112. Saito and colleagues next 
demonstrated that the LSCs of these drug resistant osteoblastic regions enter the 
cell cycle upon in vivo treatment with G-CSF. This induction of AML LSCs into the 
cell cycle sensitises them to chemotherapy-induced apoptosis and lengthens their 
survival time in patient-derived xenograft models113. Taken together, these findings 
strongly suggest that quiescent AML LSCs underpin chemotherapeutic resistance 
and that targeting of the BM niches where these quiescent LSCs reside with agents 
such as G-CSF may have therapeutic value. In spite of this potential, many of the 
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markers discussed above are not present in all LSCs or in any LSCs of certain AML 
patients. This combined with the possibility that LSCs may harbour the genetic 
instability to rapidly adapt and overcome such targeted approaches, means that 
alternative, possibly complementary means of treating AML are much needed.  
 
5.2 Targeting the BM microenvironment: the soil 
As previously described, the BM microenvironment provides an environment that 
promotes the survival, differentiation, proliferation and migration of HPSCs and their 
progeny. However, not only is this microenvironment a harbour for normal 
haematopoiesis, it also provides a rich ecosystem for LSCs to proliferate as well as 
serving as a sanctuary for these malignant cells from chemotherapy25, 114-116. The 
relative genetic stability of normal BM cells 117, 118 coupled with the targeted 
approach needed to disrupt the interaction between AML cells and their environment 
may prevent drug resistance and side effect issues inherent to chemotherapeutic 
options. The routes to targeting the BM microenvironment’s support of AML cell 
function can be divided into at least three forms that can be described in terms of 
Hanahan and Weinberg’s updated hallmarks of cancer119. Deregulation of cellular 
energetics is a feature of tumours that is intimately linked with the tumour 
microenvironment119. Therapeutic opportunities for disrupting the supply of energy 
from free fatty acid metabolism abound with many drugs already approved for use in 
humans as treatment for cardiovascular-related diseases. Two enzymatic targets 
that may be of particular promise are CPT1, the rate-limiting enzyme of fatty acid 
oxidation, and 3-ketoacylthiolase (3-KAT), which catalyses the last step in this 
process. These two pharmacological targets have shown promising effects in mice 
models however, use of CPT-1 inhibitor, etomoxir which is widely used in vitro and in 
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mice models - has shown to result in hepatotoxicity in humans. Other CPT-1 
inhibitors are still under pre-clinical assessment.  3-KAT inhibitors (Trimetazidine and 
Ranolazine), are currently approved for use in humans and have been used for the 
treatment of angina in some countries108.  
Another BM microenvironment-linked hallmark with potential as a target in AML is 
angiogenesis, which is promoted to facilitate the continuous delivery of oxygen, 
nutrients and growth factors to the ever-expanding population of malignant cells. 
Inhibiting angiogenesis has been conducted using a plethora of approaches, which 
include tyrosine kinase inhibitors, antibodies that neutralise VEGF receptors and 
other novel drugs such as statins which may indirectly affect the VEGF pathway120-
122. Bevacizumab – which has been approved for the treatment of solid tumours – is 
a monoclonal antibody that binds to a VEGF isoform and blocks it from binding to its 
receptor101, 123. However, a recent randomised trial of Bevacizumab in AML patients 
alone and in combination with standard chemotherapy did not show any 
improvement in the therapeutic outcome124. Another promising angiogenesis inhibitor 
currently under trials is Combretastatin. It is a vascular disruption agent that induces 
mitotic arrest in proliferating endothelial cells. It is currently an experimental 
treatment under phase 1 clinical trials in AML patients showing promising results and 
is well tolerated102.  Prominent angiogenesis factors within the leukaemia marrow are 
angiopoientins 1 and 2 (Ang-1/2) which are now subject of angiogenesis inhibition by 
neutralising Ang 1/2 antibody, Trenananib. This first-in-class neutralising antibody 
showed promising preliminary outcomes similar to that observed in solid tumors and 
is under further evaluation105.Inhibition of angiogenesis via interruption of receptor 
tyrosine kinases is also currently being investigated. Sunitinib, which is an inhibitor of 
several receptor tyrosine kinases (and therefore inhibits angiogenesis by 
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antagonising signalling via VEGFR1 and VEGFR2) has been approved for several 
solid tumours; however, recent in vitro and in vivo studies in AML showed a marked 
decrease in VEGF, thus production warranting clinical trials in AML patients104.  
The capacity to invade and metastasise is a unique feature of malignant tumours. To 
achieve this, tumour cells enlist a variety of mechanisms including chemotaxis and 
adhesion. Chemokine molecules such as CXCR4, adhesion molecules such as 
CD44 and VLA4, and integrin are candidate targets of the BM microenvironment that 
have been shown to interact with the LSC niche and allow tumour migration125, 126. 
Using a CXCR4 antagonist, AMD3100, studies have shown an elevated white blood 
cell count as well as mobilisation of leukaemic blasts in the peripheral blood where 
they can be subjected to the cytotoxicity of chemotherapeutic drugs106, 107. Moreover, 
work in our laboratory shows in vitro that the BTK inhibitor, ibrutinib, inhibits AML 
adhesion and migration to BMSC, hence the initiation of clinical trials of ibrutinib in 
AML92, 127. Although these approaches have yet to be fully explored, the promise of 
an effective and durable response necessitates further study analysing the 
relationship between AML and its microenvironment. Table 3 provides a summary of 
potential inhibitors of these identified interactions. 
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6. Summary 
Understanding the BM niches, their constituents and the mechanisms at play may 
hold the key to the development of methods/treatments that can directly affect the 
ability of LSCs to drive malignancy and avoid therapeutic-mediated destruction. 
Although systemic therapeutic approaches generally revolve around the direct 
elimination of malignant stem or progenitor cells, recent studies have shown that 
targeting abnormalities of the BM may have value128. Studies into how migration of 
quiescent HPSCs from the osteoblastic niche to the vascular niche wherein they 
acquire the ability to proliferate and differentiate may provide the key to the 
development of novel therapeutic approaches in the future. 
 
Practice Points 
 Clinical out-comes and prognosis in the aging population suffering from AML 
is poor as medical co-morbidities as well as a reduced haematopoietic 
reserve within the aging bone marrow present limiting factors. 
 Patient relapse following remission is due to minimal residual disease 
harboured within the bone marrow which demonstrates the importance the 
leukaemic BM microenvironment in the retention and protection of this 
disease. 
 Non- haematopoietic component of the bone marrow contributes to several 
functions such as migration, adhesion, metabolism and differentiation. 
 
Research Agenda 
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 Dissection of the multi-faceted role played by the BMSC lineages and their 
non-malignant counterparts in the survival and regulation of AML. 
 The genetic differences between the leukaemic and non-leukaemic BMSC 
may identify potential biomarkers that play a role in resistance and other 
cellular functions enhanced by the BM microenvironment. 
 Targeting the BM microenvironment to limit blast malignancy and metastasis 
without non-selective destruction of haematopoietic tissue is a more attractive 
therapeutic strategy in both young and old AML populations. 
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